Clinical Perspectives in the Use of Liquid Biopsy in Metastatic Breast Cancer

Lorenzo Gerratana, Carolina Reduzzi, Paolo D’Amico, Roberta Mazzeo, Saya Liz Jacob, Wenan Qiang, Massimo Cristofanilli*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter


Precision medicine aims to improve healthcare by identifying subsets of patients that are more likely to benefit from specific treatment strategies. Liquid biopsy offers the unique potential to better understand and monitor disease biology, since it is not burdened by the temporal and spatial limitations of tissue biopsy. CTC (circulating tumor cell) characterization is being explored as an alternative and flexible tool to identify predictive and prognostic biomarkers thanks to its capability of recapitulating a complete biological system. The present chapter will summarize the current clinical applications of CTC enumeration and its combination with other liquid biopsy technologies such as ctDNA. It will, moreover, offer new insights on non-canonical CTCs, which are emerging as a new entity with respect to epithelial circulating cells, and emerging multi-omics essays that may evolve into new comprehensive profiling workflows.

Original languageEnglish (US)
Title of host publicationCurrent Cancer Research
PublisherSpringer Nature
Number of pages26
StatePublished - 2023

Publication series

NameCurrent Cancer Research
VolumePart F1235
ISSN (Print)2199-2584
ISSN (Electronic)2199-2592


  • Breast cancer
  • Prognosis
  • Therapy response

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical Perspectives in the Use of Liquid Biopsy in Metastatic Breast Cancer'. Together they form a unique fingerprint.

Cite this